



GP1616\$

Atty. Dkt. No. 067286/0204

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: James C. Kennedy et al.

Title: Photochemotherapeutic Method using 5-Aminolevulinic Acid and Other Presursors of Endogenous Porphyrins

Appl. No.: 09/293,835

Filing Date: 4/19/99

Examiner: G. Hollinden

Art Unit: 1616

RECEIVED
SEP 19 2000
TECH CENTER 1600/2000

AMENDMENT TRANSMITTAL

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is Amendment A in the above-identified application.

[] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

[] Small Entity statement is enclosed.

[X] The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	34	20	14	x \$18.00	\$252.00
Independents:	4	3	1	x \$78.00	\$78.00
First presentation of any Multiple Dependent Claims:				+ \$260.00	\$0.00
CLAIMS FEE TOTAL:					\$330.00

[] Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$380.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$870.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,360.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,850.00	\$0.00
EXTENSION FEE TOTAL:			\$0.00
CLAIMS AND EXTENSION FEE TOTAL:			\$330.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
TOTAL FEE:			\$330.00

- ☐ Please charge Deposit Account No. 19-0741 in the amount of \$330.00. A duplicate copy of this transmittal is enclosed.
- ☒ A check in the amount of \$330.00 is enclosed.
- ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Assistant Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 12 September 2000

By



FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5109
 Telephone: (202) 672-5475
 Facsimile: (202) 672-5399

Thomas W. MacAllister
 Attorney for Applicant
 Registration No. 42,822

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 067286/0204

In re patent application of

James C. KENNEDY *et al.*

Serial No.: 09/293,835

Filed: April 19, 1999

For: **PHOTOCHEMOTHERAPEUTIC METHOD USING 5-AMINOLEVULINIC ACID
AND OTHER PRECURSORS THEREOF**



Group Art Unit: 1754

Examiner: Hollinden

RECEIVED
SEP 19 2000
TECH CENTER 1600/2800

05/12/2000 SENTINEL 00000073 09293835

01 FC:103
02 FC:104

252.00 OP
78.00 OP

Reply Under 37 CFR § 1.111

Handwritten signature/initials

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This submission responds to the Office Action that issued June 12, 2000. If Applicants have not accounted for any fees required by this response, the Commissioner is authorized to charge the missing fees to Deposit Account No. 19-0741. In the absence of an explicit request from Applicants, the PTO also is requested to grant any needed extension of time under 37 CFR 1.136, and to charge the corresponding fee to the aforementioned account. Prior to reconsideration on the merits, please amend the captioned application as set out below.

IN THE CLAIMS:

✓ Please cancel claims 11-14 and 20-23 without prejudice or disclaimer.

- Sub E2*
1. (Amended) A method of treatment comprising administering to a patient, who is suffering from a disorder associated with an agent of exogenous origin, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing the agent [or cell] to light capable of photoactivating [the porphyrin] protoporphyrin IX, wherein said disorder is characterized by the presence of lesions